Leerink Partnrs Brokers Increase Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Investment analysts at Leerink Partnrs boosted their FY2026 earnings estimates for Arrowhead Pharmaceuticals in a report issued on Tuesday, September 2nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of ($0.85) per share for the year, up from their previous forecast of ($1.57). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($1.98) EPS.

Other analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. B. Riley raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Royal Bank Of Canada reduced their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Finally, Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Buy” and an average price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $29.08 on Friday. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $29.34. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -22.72 and a beta of 1.00. The company’s fifty day moving average is $18.78 and its 200 day moving average is $16.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the company posted ($1.38) earnings per share.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals by 9.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 27,737 shares of the biotechnology company’s stock valued at $438,000 after purchasing an additional 2,444 shares during the period. Marex Group plc acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $576,000. State of Wyoming acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $142,000. Hudson Bay Capital Management LP raised its holdings in shares of Arrowhead Pharmaceuticals by 22.0% during the second quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company’s stock valued at $4,108,000 after purchasing an additional 46,870 shares during the period. Finally, Public Sector Pension Investment Board raised its holdings in shares of Arrowhead Pharmaceuticals by 7.1% during the second quarter. Public Sector Pension Investment Board now owns 428,386 shares of the biotechnology company’s stock valued at $6,768,000 after purchasing an additional 28,516 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 15,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the transaction, the insider owned 247,122 shares in the company, valued at $6,178,050. The trade was a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 25,000 shares of company stock valued at $575,000 in the last quarter. 4.30% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.